Stevens-Johnson syndrome induced by doxycycline

Cutis

Volumn 79, Issue 2, 2007, Pages 119-122

  Cac, Natalie N ^a   Messingham, Michael J ^a   Sniezek, Patrick J ^a   Walling, Hobart W ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b Dermatology PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; HUMAN; INFECTION; MALE; MIDDLE AGED; PATHOLOGY; STEVENS JOHNSON SYNDROME; TOOTH DISEASE;

DOXYCYCLINE; HUMANS; INFECTION; MALE; MIDDLE AGED; STEVENS-JOHNSON SYNDROME; TOOTH DISEASES;

EID: 33947375135     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Fritsch PO, Ruiz-Maldonado R. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. In: Fitzpatrick TB, Johnson RA, Wolff K, et al. Color Atlas & Synopsis of Clinical Dermatology. 6th ed. New York, NY: McGraw-Hill Professional; 2003:548-560.
2. Cote B, Wechsler J, Bastuji-Garin S, et al. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol. 1995;131:1268-1272.
3. Araujo OE, Flowers FP. Stevens-Johnson syndrome. J Emerg Med. 1984;2:129-135.
4. Levy M, Shear NH. Mycoplasma pneumoniae infections and Stevens-Johnson syndrome. report of eight cases and review of the literature. Clin Pediatr. 1991;30:42-49.
5. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.
6. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990;126:37-42.
7. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. an epidermiologic study from West Germany. Arch Dermatol. 1991;127:839-842.
8. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43-47.
9. Bergoend H, Loffler A, Amar R, et al. Cutaneous reactions appearing during the mass prophylaxis of cerebrospinal meningitis with a long-delayed action sulfonamide (apropos of 997 cases)[in French]. Ann Dermatol Syphiligr (Paris). 1968;95:481-490.
10. Heimbach DM, Engrav LH, Marvin J A, et al. Toxic epidermal necrolysis, a step forward in treatment. JAMA. 1987;257:2171-2175.
11. Rasmussen JE. Update on the Stevens-Johnson syndrome. Cleve Clin J Med. 1988;55:412-414.
12. Crosby SS, Murray KM, Marvin JA, et al. Management of Stevens-Johnson syndrome. Clin Pharm. 1986;5:682-689.
13. Bryant BG, Mathews BL. Stevens-Johnson syndrome. Drug Intell Clin Pharm. 1986;20:489-493.
14. Murray KM, Camp MS. Cephalexin-induced Stevens-Johnson syndrome. Ann Pharmacother. 1992;26: 1230-1233.
15. Hallgren J, Tengvall-Linder M, Persson M, et al. Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol. 2003;49 (suppl 5):S267-S269.
16. Curley RK, Verbox JL. Stevens-Johnson syndrome due to tetracyclines - a case report (doxycycline) and review of the literature. Clin Exp Dermatol. 1987;12:124-125.
17. Murphy GF, Mihm MC Jr. The skin. In: Cotran RS, Kumar V, Collins T, et al, eds. Robbins Pathologic Basis of Disease. 6th ed. Philadelphia, Pa: WB Saunders Company; 1999:1170-1214.
18. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153.
19. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child. 1922;24:526-533.
20. Thomas BA. The so-called Stevens-Johnson syndrome. BMJ. 1950;1:1393-1397.
21. Assier H, Bastuji-Garin S, Revuz J, et al. Erythema multiforme with mucous membrane involvement and Steven-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131:539-543.
22. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.
23. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
24. Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch Dermatol. 1993;129:466-468.
25. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33-36.
26. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology. 2003;207:96-99.
27. Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323-327.
28. Gallais V, Randrianjohanny A, Robineau M, et al. Stevens-Johnson syndrome caused by doxycycline [in French]. Presse Med. 1997;26:855.